411 related articles for article (PubMed ID: 24745023)
1. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.
Gori M; Arciello M; Balsano C
Biomed Res Int; 2014; 2014():741465. PubMed ID: 24745023
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
4. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
[TBL] [Abstract][Full Text] [Related]
5. NAFLD-related HCC.
Banini BA; Sanyal AJ
Adv Cancer Res; 2021; 149():143-169. PubMed ID: 33579423
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
7. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
9. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
10. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
11. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
12. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
[TBL] [Abstract][Full Text] [Related]
13. Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma.
Rana M; Saini M; Das R; Gupta S; Joshi T; Mehta DK
Microrna; 2023; 12(2):99-113. PubMed ID: 37005546
[TBL] [Abstract][Full Text] [Related]
14. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
[TBL] [Abstract][Full Text] [Related]
16. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
17. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
[TBL] [Abstract][Full Text] [Related]
18. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Michelotti A; de Scordilli M; Palmero L; Guardascione M; Masala M; Roncato R; Foltran L; Ongaro E; Puglisi F
Cells; 2021 Aug; 10(8):. PubMed ID: 34440803
[TBL] [Abstract][Full Text] [Related]
19. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.
Zhao F
Adv Exp Med Biol; 2018; 1061():79-93. PubMed ID: 29956208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
